Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous
Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous system. In May 2000, Epix granted Schering a worldwide, nonexclusive, royalty-bearing license for the sale of Eovist, an investigational MRI contrast agent for liver imaging. The patents are owned by the Massachusetts General Hospital and licensed exclusively to Epix, which will receive upfront payments made up of a license fee, royalties on past sales, prepayment of future royalties, and a contingent license fee based on marketing approval of Multihance in the U.S.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.